share_log

康哲藥業：自願性及業務進展公告 創新藥高選擇性TYK2抑制劑CMS-D001及GnRH受體拮抗劑CMS-D002獲藥物臨床試驗批准通知書

CMS: Voluntary and Business Update Announcement Approvals of Drug Clinical Trials for Innovative Drugs Highly Selective TYK2 Inhibitor CMS-D001 and GnRH Receptor Antagonist CMS-D002

香港交易所 ·  Feb 7 07:08
Summary by Moomoo AI
康哲藥業宣佈，旗下兩款自主研發的創新藥物CMS-D001和CMS-D002近期獲得中國國家藥品監督管理局（NMPA）的臨床試驗批准。CMS-D001為高選擇性TYK2抑制劑，擬用於治療銀屑病等免疫炎症性疾病，而CMS-D002為GnRH受體拮抗劑，未來可用於治療子宮內膜異位症等疾病。兩款藥物將進行I期臨床研究，評估其安全性、耐受性、藥代動力學和療效。本次臨床試驗批准為康哲藥業在創新藥物研發領域的重要進展，有望為相關疾病患者提供更優的治療選擇。
康哲藥業宣佈，旗下兩款自主研發的創新藥物CMS-D001和CMS-D002近期獲得中國國家藥品監督管理局（NMPA）的臨床試驗批准。CMS-D001為高選擇性TYK2抑制劑，擬用於治療銀屑病等免疫炎症性疾病，而CMS-D002為GnRH受體拮抗劑，未來可用於治療子宮內膜異位症等疾病。兩款藥物將進行I期臨床研究，評估其安全性、耐受性、藥代動力學和療效。本次臨床試驗批准為康哲藥業在創新藥物研發領域的重要進展，有望為相關疾病患者提供更優的治療選擇。
Conge Pharmaceuticals announced that its two independently developed innovative drugs CMS-D001 and CMS-D002 have recently received clinical trial approval from the National Drug Administration of China (NMPA). CMS-D001 is a highly selective TYK2 inhibitor intended for the treatment of immunoinflammatory diseases such as psoriasis, while CMS-D002 is a GnRH receptor antagonist that could be used in the future to treat diseases such as endometriosis. The two drugs will undergo Phase I clinical trials to assess their safety, tolerability, pharmacokinetics and efficacy. The approval of this clinical trial marks an important advance in the field of innovative drug development by Conch Pharmaceuticals, which is expected to provide better treatment options for patients with related diseases.
Conge Pharmaceuticals announced that its two independently developed innovative drugs CMS-D001 and CMS-D002 have recently received clinical trial approval from the National Drug Administration of China (NMPA). CMS-D001 is a highly selective TYK2 inhibitor intended for the treatment of immunoinflammatory diseases such as psoriasis, while CMS-D002 is a GnRH receptor antagonist that could be used in the future to treat diseases such as endometriosis. The two drugs will undergo Phase I clinical trials to assess their safety, tolerability, pharmacokinetics and efficacy. The approval of this clinical trial marks an important advance in the field of innovative drug development by Conch Pharmaceuticals, which is expected to provide better treatment options for patients with related diseases.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more